Walid Kamoun Highlights Next-Generation In Vivo Antibody–ADC Click Technology - Oncodaily

Wits University news releaseIn a landmark HIV prevention trial, an antibody blocked viruses most vulnerable to it, but others broke through. Now researchers have uncovered how HIV evolved after those infections – and why the amount of antibody in the body is an essential part of the story. The Antibody-Mediated Prevention (AMP) trials enrolled more than 4,600 volunteers across Africa, the Americas, and Europe to test VRC01, a laboratory-made broadly neutralising antibody (bnAb). In the AMP trial, VRC01 did not significantly reduce HIV infections overall, although it reduced infections caused by highly sensitive strains by about 75%.  This study showed that HIV requires high antibody titers, and it illustrates the importance of maintaining those titers throughout the dosing cycle. A new study published in Nature Microbiology has now examined what happened after infection in people who received VRC01. The findings show how a virus can respond to antibody pressure – and offer clues for improving future antibodies and vaccines. Read the full news release here.

Upgrading to a WiFi 7 router just got easier PC Guide is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Read More

Here’s your NYT Strands hint for today, plus the spangram and all of today’s Strands answers for puzzle No. 959 on Sunday, Oct. 18, 2026. Today’s Strands theme was tricky. It helps to be a runner. Read on for all the answers.